Exploring Sanofi's Revamped IO Pipeline
Executive Summary
In an exclusive interview, Sanofi's head of oncology development Joanne Lager explains how the French big pharma could make a comeback in cancer this year and highlights its immunotherapy combination opportunities.
You may also be interested in...
Regeneron Tries To Put Focus On PD-1 Program, Not Sluggish Autoimmune Sales
Regeneron promised big things for PD-1 inhibitor cemiplimab during its first quarter earnings call, including studies to test its potential in lung cancer compared to Merck's Keytruda. It hopes to launch the antibody in a smaller indication later this year.
Six New Molecules By 2030 – J&J’s Neuroscience Strategy
Can neuroscience be precise? Peter Fang, worldwide VP of neuroscience, explains J&J's approach to precision medicine in Alzheimer’s disease, depression and other neurological conditions.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.